Abata Therapeutics has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata’s continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Unusually active option classes on open August 13th
- Aethlon Medical receives ethics approval for clinical trial of Hemopurifier
- Bristol Myers price target raised to $53 from $45 at TD Cowen
- Truist biotech analyst holds an analyst/industry conference call
- Bristol Myers Stock (NYSE:BMY): Perfect Place to Wait Out Market Volatility